Ibnsina Pharma · EGX:ISPH
Ibnsina Pharma — FY2025 Earnings Presentation
15 slides from Ibnsina Pharma's earnings presentation, Mar 3, 2026
Slide 1: 2025 Business Review Earning Call
2025 Business Review Earning Call 3 March 2026 1
Slide 2: Performance Highlights: FY 2025
Performance Highlights: FY, 2025 Growth Profitability Balance Sheet Cash Flow 30.2% 55% 18% 285mn Market Growth in Debt Ratio FCFE EBITDA vs 20%, FY 24 vs -269mn, 24 Share Market Growth: 41% 25: 3.9bn | M: 5.1% 24: 2.5mn | M: 4.5% 38% 55% 1.97 1.4 1bn Growth in Growth in Net Debt : Net Debt : FCFF R
Slide 3: Market & Company Growth
Market & Company Growth Market Forces Revenue FY 23 – 25 | Bn. FY 23 – 25 | Bn. 206bn | G: 29% 292bn | G: 41% 410bn | G: 41% Market FY, 2023 FY, 2024 FY, 2025 1 Leader 33% 90 70% 110 114 (3 Years) Revenue CAGR 38% 95 20 - 25 80 91 92 60% 81 70 57 62 59 61 65% 50% 42 46 1,000 140 60 100 0.00000 0 938
Slide 4: Pharma Business Growth
Pharma Business Growth Pharmacies Wholesalers Hospitals Contribution Revenue Analysis Revenue Analysis Revenue Analysis By Segment 23 – 25 (Mn.) 23 – 25 (Mn.) 23 – 25 (Mn.) 23 -25 300 00 80% 45,000 90% 36% 34% 70% 40,000 80% 250 00 39,515 24,814 52% 160 00 70% 35,000 70% 60% 15,048 31% 140 00 60% 30
Slide 5: Subsidiaries & BUs
Subsidiaries & BUs Non-pharma Ibnsina Pharma’s Ramp FMCG Distribution Scientific Office Logistics 2021 2023 2021 5
Slide 6: Subsidiaries & BUs
Subsidiaries & BUs Non-pharma Ibnsina Pharma’s Ramp FMCG Distribution Scientific Office Logistics 2021 2023 2021 Revenues Net Profit 250 Revenues 180 % Net Profit Revenues68% Net Profit 83% 41% 45% 400 70% 5,000 60% 140 % 160 % 34% CAGR CAGR CAGR 350 68% 22 - 25 4,500 200 21 - 25 23 - 25 140 % 120 %
Slide 7: Margin Analysis
Margin Analysis FY Margin Analysis +0.5% 2023 - 2025 Increase 8.4% 7.9% 7.4% +0.6% Increase +0.6% Increase +0.1% 5.1% Increase 4.5% 4.6% 2.5bn 4.4bn 6.4bn 1.2% 3.9% 4.0% Value Value Value 1.1% 3.3% 1.3bn 2.5bn 3.9bn 0.6% Value Value Value 1.1bn 2.2bn 3.5bn 214mn 615mn 952mn Value Value Value Value V
Slide 8: OPEX vs EBITDA Analysis
46% 18% OPEX vs EBITDA Analysis Digital Sales Growth Retail Sales Share 664mn 1,328mn 2,508mn 3,880mn FY EBITDA FY EBITDA FY EBITDA FY EBITDA +664mn +1,180mn +1,372mn 100% 89% 55% Growth Growth Growth 5.1% 5.1% 5.1% 5.1% 4.5% 4.5% 4.5% 4.3% 4.3% 4.2% 4.1% 4.1% 4.2% 4.0% 3.9% 3.9% 3.6% 3.5% 3.4% 3.1%
Slide 9: Income Statement
ISP Consolidated Income Statement ISP Standalone AIM Consolidated Gross Sales (Growth: 38%) Gross Profit (Growth: 47%) OPEX (Growth: 40%) EBITDA (Growth: 55%) 80,092 6,449 3,880 (8.4%) 2,332 (5.1%) 99 (3.0%) 377 57,910 4,397 62 (7.9%) 1,665 32 (3.0%) 2,508 232 (4.5%) 40 11 35,004 2,515 1,098 29 79,7
Slide 10: Deleveraging the Business
Deleveraging the Business Net Debt +671mn Net Debt to Equity Increase -0.4 1.2bn 7.3 Decrease Assets HFS 6.5 6.6 3.0 3.1 5.5 2.7 2.6 2.6 4.8 2.4 2.4 2.4 2.2 2.3 1.9 2.0 Outstanding 3.5 3.2 3.7 3.3 3.8 3.7 3.5 Collection Performance Q1 23 S1 23 9M 23 FY 23 Q1 24 S1 24 9M 24 FY 24 Q1 25 S1 25 9M 25 FY
Slide 11: Financial Expenses to EBITDA
Financial Expenses to EBITDA 100 % 57.00 % Int: 477mn | EBITDA: 664mn Int: 1.0bn | EBITDA: 1.3bn Int: 1.7bn| EBITDA: 2.5bn Int: 2.6bn | EBITDA: 3.9bn 8,000 2.1%| 3.0% 3.1%| 3.9% 3.0%| 4.5% 3.3%| 5.1% 90% 1,200 5.0% 5.0% 80% 7,000 47.00 % 5.2% 1,000 70% 6,000 5.1% 4.5% 60% 800 37.00 % 5,000 4.5% 3.8%
Slide 12: Cash Conversion Cycle
Cash Conversion Cycle Q1 2024 S1 2024 9M 2024 FY 2024 Q1 2025 S1 2025 9M 2025 -4 FY 2025 Decrease 2.0 1.3 0.0 2.9 9.9 13.5 10.7 6.7 Days of Cash Days of Cash Days of Cash Days of Cash Days of Cash Days of Cash Days of Cash Days of Cash Conversion Conversion Conversion Conversion Conversion Conversio
Slide 13: Cash Flow Analysis
Cash Flow Analysis Free Cash Flow Analysis FY22 FY23 FY24 FY25 FCFF vs FCFE 22 - 25 CFO 843 1,056 449 2,200 1,041 - (Financial Interest) (482) (930) (1,375) (2,271) = Net CFO 362 126 (927) (71) 612 + Interest Paid (Tax Adjusted) 373 721 1,066 1,760 - (Net CAPEX) (1,376) (280) (260) (648) = FCFF (641
Slide 14: 2026's Guidance
EGP 3,252mn 2026’s Guidance % : Sales: 3.3% SG&A (+877mn) Assumptions 2026: 32.0% Investment +1.8% 24 - 25 12% 120 , 00 30% 100 0.0005 80% 20.0bn 75% 15% 900 . 005 70% Difference 9,000 1.5bn 25% 800 . 005 60% Difference Market Growth 700 . 005 100 , 00 25% 50% (11% ASP, 4% Units) 600 . 005 100,000 8
Slide 15: ibnsinapharma
ibnsinapharma